Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA Negotiations: Early Communications, Breakthrough Still On Docket

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA and industry also talking about improvements to combination product review process as part of user fee program renewal.

You may also be interested in...



FDA's Breakthrough Workload Will Be Eased By Hiring Reviewers With PDUFA VI Funds

User fees won't support dedicated staff, but rather FTEs that will work on the popular program as needed.

Sponsors, FDA Reviewers To Get More Flexibility Under New User Fee Program

Next iteration of PDUFA will feature new communication plans that allow FDA and sponsors to drop mid-review meetings if desired.

FDA's Breakthrough Bar May Be Set Too Low, Jenkins Says

Office of New Drugs Director recommends that EMA be careful how its sets the bar for its similar PRIME program to ensure it remains meaningful.

Related Content

Topics

UsernamePublicRestriction

Register

PS079121

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel